代谢相关脂肪性肝病的流行病学现状及诊治研究进展  

Research advances in epidemiological situation and diagnosis and treatment of metabolism-associated fatty liver disease

作　　者：庄颖洁 刘文徽[1] 刘正一 高利利[1] Zhuang Ying-Jie;Liu Wen-Hui;Liu Zheng-Yi;Gao Li-Li(Department of Gastroenterology,the Second Medical Center of Chinese PLA General Hospital/National Clinical Medical Research Center for Geriatric Diseases,Beijing 100853,China;Chinese PLA Medical School,Beijing 100853,China)

机构地区：[1]解放军总医院第二医学中心消化内科/国家老年疾病临床医学研究中心,北京100853 [2]解放军医学院,北京100853

出　　处：《解放军医学杂志》2023年第12期1457-1466,共10页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金面上项目(81570563)。

摘　　要：代谢相关脂肪性肝病(MAFLD)曾用名非酒精性脂肪性肝病(NAFLD),是全球最流行的慢性肝脏疾病之一,已经成为肝硬化、终末期肝病及原发性肝癌的主要原因之一。近年来MAFLD患病率在中国及亚太地区,甚至全球逐渐增高,加重了医疗及社会经济负担,国内外对该病的流行病学及危险因素的探索也逐渐增多。同时,由于MAFLD治疗药物少,其药物治疗也成为临床亟待解决的热点问题,近年进入临床试验阶段的药物明显增多。基于此,本文针对当前MAFLD的流行病学现状、危险因素、诊断标准及治疗研究进展进行综述,以期为MAFLD的临床诊疗及科研提供新的思路与方向。Metabolism-associated fatty liver disease(MAFLD),formerly known as non-alcoholic fatty liver disease(NAFLD),is one of the most popular chronic liver diseases in the world,and has become one of the main causes of liver cirrhosis,end-stage liver disease,and primary liver cancer.In recent years,the prevalence of MAFLD has gradually increased in China,the Asia Pacific region,and even globally,increasing the medical and socio-economic burden.The exploration of the epidemiology and risk factors of this disease at home and abroad has also gradually increased.Meanwhile,due to the scarcity of MAFLD treatment drugs,their drug treatment has become a hot issue that needs to be urgently addressed in clinical practice.In recent years,there has been an increase in the number of drugs entering the clinical trial stage.Based on this,the current epidemiological status,risk factors,diagnostic criteria,and treatment research progress of MAFLD have been reviewed in order to provide new ideas and directions for the clinical diagnosis,treatment,and scientific research of MAFLD.

关 键 词：非酒精性脂肪性肝病 流行病学 危险因素 诊断 治疗学 

分 类 号：R575[医药卫生—消化系统]